Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
VRTX News
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $499 from $467 and keeps an Equal Weight rating on the shares. The company announced...
Wolfe Research analyst Andy Chen last night downgraded Vertex Pharmaceuticals (VRTX) to Peer Perform from Outperform without a price target The company’s Q1 ear...
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings p...
Analyst ratings
51%
of 35 ratingsMore VRTX News
recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge relate...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...
Prior guidance was $11.75B-$12.0B. The company states: “Vertex today raised the low end of its full-year 2025 revenue guidance range from $11.75 to $12 billion...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.3...
Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5. Analysts expect the Bost...
In a report released on May 2, Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target o...